Cigna CEO regretted deal with Anthem before it fell apart

Amy Baxter | | Health Exec | Management

In the midst of breakup woes that include a court fight, the failed merger between Cigna and Anthem apparently weighed heavily on the mind of Cigna’s CEO, David Cordani, before it even fell apart. According to Bloomberg, Cordani privately expressed regret he had agreed to the deal that would have left him in a reduced role.

Had the merger gone through, Anthem CEO Joseph Swedish would have led the combined company, Bloomberg reported.

The potential deal, which was worth approximately $50 billion, ended in 2017. It would have created the nation’s largest health insurance provider. The two companies are still dealing with the fallout; Cigna and Anthem have both launched lawsuits against each other to cover the bills of the merger exploration, including a $1.85 billion fee.

Anthem has accused Cordani of sabotaging the deal, while Cigna has blamed Anthem managers for obstacles in the antitrust process. Reportedly, Cordani said his “soul was still unsettled” by the deal as the merger exploration was underway, Bloomberg reported.

See the full story below:

Cigna’s CEO Expressed Regret About the Anthem Merger That Later Failed

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.